Abstract | Prostate cancer is responsible for the deaths of more than 33,000 American men every year. Once this disease has become metastatic, there is no curative treatment. Alternative therapies to chemotherapy and radical prostatectomy are being increasingly explored. Prostate cancer vaccines-which trigger a tumour-specific cytotoxic-T-lymphocyte-mediated immune attack by the patient's immune system-have been investigated in clinical trials with modest, yet encouraging, results. When developing and administering prostate cancer vaccines, it is critical to consider how vital parameters, such as the stage of disease progression and the nature of adjuvant therapies, could influence treatment outcome. Of particular interest are current and future strategies for diminishing the activity of regulatory T lymphocytes.
Introduction
Prostate cancer is the second leading cause of cancerrelated deaths among men in the USA. 1 First-line treatment options include radiotherapy, radical prostatectomy, cryosurgery, and hormonal therapy. Following initial treatment, more than one-third of patients will experience biochemical recurrence and tumour progression to castration-resistant prostate cancer (CRPC), for which there is no effective cure. Biochemical recurrence is defined as an increase in serum levels of PSA, which is usually followed by a slow progression to detectable metastasis (median duration of 7 years). 2 Given that CRPC is responsible for the vast majority of prostatecancer-related deaths, treatment modalities for disease recurrence should be systemic. The current 'gold standard' first-line treatment for patients with CRPC is the taxane docetaxel (plus prednisone). However, chemotherapeutic drugs only modestly enhance patient survival and cause a wide range of undesirable adverse effects. 3 Alternative, or adjuvant, therapies, such as p rostate cancer vaccines, are urgently needed.
In most studies, prostate cancer vaccines have been shown to be safe and well tolerated. 4 Indeed, the results from a randomized phase III trial led to FDA approval of the therapeutic prostate cancer vaccine sipuleucel-T® (Dendreon Corporation, Seattle, USA). Sipuleucel-T is now available for patients with asymptomatic or minimally symptomatic metastatic CRPC. 5 In this Review, we focus specifically on the potential mechanisms of action for all prostate cancer vaccines that trigger cytotoxic T lymphocyte (CTL)-mediated responses and have reached clinical trials. We discuss ways in which key immune events are likely to affect the efficacy of each vaccine and consider how information regarding these potential mechanisms can be exploited for future c ombinatorial treatments.
Prostate cancer vaccine principles
There are many reasons why prostate cancer is a good candidate for attack by the adaptive immune system. Firstly, prostate cancer cells are generally slow-growing, allowing time for an effective immune response to develop. 6 Secondly, the prostate expresses many tissuespecific proteins that can serve as immune targets. Thirdly, it has been suggested that the prostate gland is immunologically ignored, enabling prostate-cancervaccine-mediated activation of the patient's own prostatespecific CTLs (as these have not been centrally deleted). 7 Most prostate cancer vaccines-and cancer vaccines in general-are designed to generate tumour-specific CTLs. Tumour specificity is usually determined by a tumourassociated antigen (TAA)-the key immuno gen of the vaccine. TAAs can be prostate-specific, mutated, aberrantly expressed, or anachronistically expressed. With an effective vaccination strategy, TAA-expressing prostate tumour cells can be potentially targeted and destroyed by TAA-specific CTLs, with very little damage caused to healthy tissue outside of the prostate gland. Many potential TAAs have been identified in prostate carcinomas and examples of these prostate-related TAAs include PSA, prostate-specific membrane antigen (PSMA), and prostatic acid phosphatase (PAP). 8 Dendritic cells are key mediators of the immune system and are usually principle intermediates in the therapeutic action of cancer vaccines. 9 Alternatively, dendritic cells can be used as the vaccine vehicle.
need to endocytose the immunogen in particulate form or endogenously express the immunogen to promote CTL stimulation over B lymphocyte activation. It is imperative that the dendritic cell also simultaneously receives an activation/maturation signal, often referred to as a danger signal. 12, 13 Danger signals are molecular structures derived from exogenous foreign pathogens or endogenous 'stressed' or dying cells. Examples of danger signals include granulocyte-macrophage colonystimulating factor (GM-CSF), viral and bacterial components, and endogenous proteins, such as high-mobility group box 1 protein (HMGB1), which can be released by the host's dying tumour cells.
14-17

Virus-based vaccines
One of the potential benefits of virus-based cancer vaccines is their immunogenicity. Certain virus-based cancer vaccines-for example, adenovirus-based vacci nespossess inherent danger signals capable of promoting dendritic cell maturation, rendering them particularly potent. 16 Recombinant attenuated viruses-constituting the most common form of virus-based cancer vaccines-are very efficient at in vivo transduction, resulting in substantial endogenous expression of encoded cargo (such as TAAs). Finally, virus-based cancer vaccines can be manufactured as 'off the shelf ' products that require no individualization-for example, PROSTVAC® VF (Bavarian Nordic, Kvistgaard, Denmark).
PROSTVAC® VF PROSTVAC® VF, or PSA-TRICOM, is an optimized hetero logous prostate cancer vaccine designed by the National Cancer Institute. It consists of a prime and multiple boosts with attenuated vaccinia and fowlpox viruses, respectively. 18 Both recombinant viruses are vectors for DNA that encodes human PSA and the co-stimulatory proteins CD54, CD58, and CD80. Preclinical studies established that this triad of co-stimulatory proteins (coencoded with a TAA) was more effective at stimulating TAA-specific CTL activity and antitumour responses than vaccines containing none, one, or two of these costimulatory polypeptides. 19 In subsequent phase II clinical trials, PROSTVAC® VF extended the lives of men with prostate cancer by approximately 9 months compared with controls. 20, 21 This benefit was particularly evident in patients with less advanced or less aggressive disease. On the basis of this finding and other data, it has been suggested that cancer vaccines for prostate cancer are more likely to benefit patients with less advanced disease. Understanding the mechanisms of action for cancer vaccines is vital when considering future combinatorial approaches. In the PROSTVAC® VF phase II clinical trials, patients with greater PSA-specific CTL responses demonstrated enhanced survival, suggesting that the vaccine was achieving its desired immunological effect. 21 For most of the prostate cancer vaccines that have been investigated in clinical trials to date (including PROSTVAC® VF), the primary mechanism of action can only be deduced from analysis of both clinical and preclinical data. It is possible that PROSTVAC® VF stimulates an antitumour response in an environment of impaired dendritic cell function. The vaccinia virus is known to have multiple strategies for evading immune attack via impairment of host immune responses. 23, 24 Although it is unclear whether this virus directly impairs dendritic cell maturation, 25, 26 inhibition of MHC class II presentation by the vaccinia virus has been shown to abrogate CD4 + T lymphocyte activation. 25 Indirect evidence to suggest that PROSTVAC® VF is a poor stimulator of CD4 + T lymphocytes comes from the finding that patients vaccinated with PROSTVAC® VF rarely produce detectable levels of PSA-specific antibodies. 20 However, the vaccinia virus can infect mature dendritic cells, enabling them to directly activate CD8 + T lymphocyte responses. 27 There are at least two (nonexclusive) pathways by which PROSTVAC® VF might activate tumour-specific CD8 + T lymphocytes ( Figure 1) . Poxviruses, such as the vaccinia virus used in the PROSTVAC® VF prime, are capable of infecting both somatic cells and dendritic cells via macropinocytosis. 28 Infected cells then co-express recombinant co-stimulatory proteins (CD54, CD58, and CD80) and MHC class I/PSA antigens. In the first pathway, the vaccinia virus infects both immature and mature dendritic cells, which then travel to draining lymph nodes and co-express co-stimulatory proteins and MHC class I/PSA epitopes. Upon reaching the lymph nodes, these cells trigger the activation and proliferation of PSA-specific CD8 + T lymphocytes via interaction with T-cell receptors and complementary co-stimulatory ligands (CD11a/CD18, CD2, and CD28). These activated PSA-specific CTLs then circulate to sites of metastasis and induce programmed cell death (PCD) of tumour cells.
In the second pathway, the vaccinia virus infects somatic cells, which then directly activate PSA-specific CTLs and possibly natural killer cells to induce PCD of infected somatic cells (Figure 1 ). The dying cells are then taken up by dendritic cells that cross-present PSA and stimulate PSA-specific CTLs in draining lymph nodes, resulting in further PCD of tumour cells. The role of natural killer cells in PROSTVAC® VF vaccination has not yet been investigated, but it is likely that some naturalkiller-mediated killing of vaccinia-virus-infected somatic cells occurs, possibly via natural cytotoxicity receptors. 29 This process would then indirectly contribute towards further PSA-specific CTL activation. However, it should be noted that no strong evidence exists to support this second pathway at present and, unlike adenoviral components, poxviral components are known to suppress innate activation pathways in dendritic cells. 30 ,31
REVIEWS
Almost as a matter of routine, the pleiotropic cytokine GM-CSF is co-delivered with PROSTVAC® VF at, or near, the site of vaccination. Patients receive oncedaily injections of 100 μg GM-CSF subcutaneously on the day of each vaccination and for 3 consecutive days. However, the role and efficacy of GM-CSF as an adjuvant for PROSTVAC® VF in a clinical setting remains unclear and is primarily based on mouse studies and a single phase II trial, which rendered conflicting results. 21, 32 To elaborate, in a particularly salient study of a transgenic mouse model for colon cancer, it was shown that the poxvirus vaccine regime (similar to that of PROSTVAC® VF) was only effective at extending the survival of tumour-challenged mice when GM-CSF was supplied once-daily for 4 days (prime only) as an adjuvant. 32 Although a recent phase II clinical trial noted no difference in T cell responses or survival (as determined by Halabi nomogram) in patients with metastatic CRPC, it should be noted that only a small number of patients (approximately eight per treatment group) were studied. 21, 33 A phase III trial is currently aiming to recruit 1,200 patients with asymptomatic or minimally symptomatic metastatic CRPC to further assess the efficacy of GM-CSF (NCT01322490).
Combination therapy with PROSTVAC® VF
Combining PROSTVAC® VF with agents that target the suppressive arm of the immune response is important given the reported influence of the effector:regulatory lymphocyte ratio on the efficacy of cancer vaccines. Thus, it is likely that cancer vaccines will require adjuvant codelivery, aimed at inhibiting or reducing levels of regulatory T lymphocytes and promoting effector lymphocyte responses. One way of achieving this is to target regulatory T lymphocytes using antibodies against negative regulators of the adaptive response, such as the immunological checkpoint molecules cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1). Although phase I trials have shown that the combi nation of PROSTVAC® VF and ipilimu mab (a CTLA-4 antagonist) is generally safe and well tolerated, 34 a potential drawback of this approach is that the anti-CTLA-4 activity of ipilimumab could result in an aggressive autoimmune response. 35 PD-1, which shares homology with CTLA-4, could be a safer alternative target. Indeed, a phase I clinical trial of patients with a range of cancers, including men with CRPC, demonstrated that the human anti-PD-1 antibody MDX-1106 was well tolerated to the maximum dose of 10 mg/kg. 36 Conclusive direct comparisons between ipilimumab and MDX-1106 are yet to be performed; however, these early data suggest that MDX-1106 therapy could result in fewer and milder immune-related adverse effects (such as inflammatory colitis) than ipilimumab. 36 There is also evidence from murine melanoma models that combining anti-CTLA-4 and anti-PD-1 could further enhance the potency of cancer vaccines such as GVAX by promoting a more inflammatory, rather than suppressive, tumour microenvironment. 37 Prostate cancer vaccines could also be enhanced by such a combination.
If regulatory T lymphocyte targeting proves to be effective, a future avenue of research might be to target tumours or draining lymph nodes (at sites of vaccination) with a combination of PROSTVAC® VF and nanoparticulated regulatory T lymphocyte antagonists such as ipilimumab and MDX-1106. This approach would localize the ablation, or dampening, of regulatory T lymphocyte function to the relevant microenvironments and minimize autoimmune adverse effects. When delivered systemically, cargo-carrying nanoparticles such as long-circulating liposomes carrying doxorubicin-for example, Doxil® (Janssen Biotech, Inc., Horsham PA, USA)-are known to preferentially accumulate in tumours via a phenomenon known as the 'enhanced permea bility and retention' effect. 38, 39 In theory, therefore, nanoparticles carrying agents that ablate regulatory T lymphocyte function can be used to target tumours and enhance immune-mediated tumour cell killing.
Alternatively, or additionally, one could potentially target the draining lymph nodes with cargo-carrying nano particles at the site of vaccination. Nanoparticles in the size range of 20-200 nm are known to freely drain to lymph nodes without the aid of dendritic cells. 40 Dampening regulatory T lymphocyte activity in this way could improve the immunopotency of the PROSTVAC® VF vaccine and any other cancer vaccines for which r egulatory T lymphocytes are of concern.
Combining PROSTVAC® VF with strategically administered chemotherapy could, ultimately, provide Figure 1 | Proposed mechanisms of PROSTVAC® VF action. In pathway 1, the vaccinia virus infects immature or mature DCs, which travel to draining lymph nodes and express co-stimulatory proteins and MHC class I/PSA epitopes (1a). These cells then trigger the activation and proliferation of PSA-specific CD8 + T lymphocytes (1b), which circulate to tumour sites and kill tumour cells via PCD (1c). In pathway 2, the vaccinia virus infects somatic cells (2a), which then directly activate PSA-specific CTLs (2b) and NK cells (2b'). These cells then induce PCD of somatic cells (2c and 2c'), which are taken up by DCs that are activated by viral components to mature and crosspresent PSA (2d). These mature DCs further stimulate PSA-specific CTL activation (2e), causing PCD of tumour cells (2f). Abbreviations: CTL, cytotoxic T lymphocyte; DC, dendritic cell; NK cell, natural killer cell; PCD, programmed cell death.
substantial benefit to men with prostate cancer. However, clinical trials of this combination have yet to be performed. Randomized phase II clinical trials of men with CRPC treated with a predecessor to PROSTVAC® VF-docetaxel plus admixed vaccinia encoding PSA and CD80, followed by avipox-PSA boosts 41 -found that chemotherapy did not interfere with, and might even have improved, PSA-specific response. Docetaxel does not preferentially dampen immunosuppressive cell populations and, therefore, is likely to enhance antitumour immune responses by other means. In a tolerogenic murine model, a combination of CEA/TRICOM (a poxvirus-based vaccine that is similar to PROSTVAC® VF) and docetaxel provided greater therapeutic benefit than either treatment alone. 42 It was shown that, although docetaxel had no effect on regulatory T lymphocytes, its presence resulted in enhanced production of IFN-γ by CD8 + T lymphocytes. Future research could help to maximize the efficacy of the PROSTVAC® VF vaccine. Passive or active tumour targeting with nanoparticulated chemo therapeutic drugs or use of low-dose chemotherapy regimens could substantially alleviate adverse effects. Choice of the chemotherapeutic agent is crucial as there are certain chemotherapeutic drugs that, aside from their direct tumoricidal properties, can also promote antitumour immune responses. For instance, cyclophosphamide and 5-fluorouracil are capable of selectively depleting immunosuppressive cellular populations such as regulatory T lymphocytes and myeloid-derived suppressor cells (MDSCs), respectively. 43, 44 Also, anthracyclines (for example, doxorubicin) are known to induce immuno genic tumour cell death. 45 Preclinical data support the combined use of these agents with prostate cancer vaccines. 46 These studies have noted the synergistic antitumour benefits of combining doxorubicin and cyclophosphamide.
Ad5-PSA
There is mounting evidence to suggest that adenoviruses can act as suitable TAA vectors and these agents represent one of the most efficient methods for gene delivery in vivo for vaccine applications. As replication-deficient recombinant adenovirus type 5 (Ad5) vectors are efficient at transducing genes to a range of cell types, these vectors are strong candidates for the delivery of TAAs.
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Ad5 and other Ad strains (for example, Ad35) are also useful adjuvants for recombinant TAA genes, owing to their inherent ability to potently infect and stimulate dendritic cells. 15, 16 Administration of Ad5-PSA admixed with the collagen matrix Gelfoam® (Pharmacia & Upjohn Company LLC, Memphis, TN, USA) results in stronger immune responses and protection from high-titre antiadenovirus antibodies compared with Ad5-PSA alone. 48 A phase I clinical trial of men with prostate cancer and evidence of metastatic disease established a correlation between T lymphocyte response and patient survival. 49, 50 Patients in this trial received a single dose of Ad5-PSA, highlighting the immunopotency of Ad5. If Gelfoam® can consistently prevent neutralization by host Ad5 antibodies, Ad5 vectors might be more immunogenic than vaccinia or canarypox vectors. 49 It seems likely that activation of PSA-specific CTLs by Ad5-PSA vaccination occurs via direct stimulation by infected dendritic cells, potentially with input from CD4 + T lymphocytes. Ad5-PSA can directly infect immature dendritic cells via a receptor-mediated process, 15 resulting in dendritic cell maturation 16 and presentation of MHC class I/PSA epitopes ( Figure 2 ). In addition, Ad5-PSA is capable of infecting somatic cells, which can be subsequently recognized and destroyed by natural killer cells. 51 By targeting an E1A-independent pathway involving interaction between NKG2D and stress-induced proteins, 52 natural-killer-cell-mediated killing can result in the uptake of apoptotic bodies by immature dendritic cells. These apoptotic bodies comprise, not only viral components that could promote dendritic cell maturation, but also tumour antigens (to be presented as MHC class II/PSA epitopes). Within the lymph node, activated dendritic cells can trigger the activation and proliferation of PSA-specific CD8 + T lymphocytes, possibly with the aid of activated CD4 + T lymphocytes (which supply additional IL-2). 51 PSA-specific CTLs then circulate to tumour sites and kill tumour cells via PCD. 4 In terms of future combinatorial treatments, Ad5-PSA vaccines might benefit from the addition of regulatory T lymphocyte antagonists to an even greater extent than PROSTVAC® VF as, unlike poxviruses, adenoviruses In addition, Ad5-PSA infects somatic cells (2a) which are then recognized (2b) and killed (2c) by NK cells via an E1A-independent pathway involving interaction between NKG2D and stress-induced proteins. NK-mediated killing generates apoptotic bodies (2d), which are taken up by immature DCs (2e). These bodies promote DC maturation and presentation of PSA epitopes in association with MHC class II molecules (1b). In the lymph node, activated DCs trigger the activation and proliferation of PSA-specific CD8 + T lymphocytes (1c), possibly with the aid of activated CD4 + T lymphocytes (1c'), which supply additional IL-2 (1d). PSA-specific cytotoxic T lymphocytes then circulate to tumour sites and kill tumour cells via programmed cell death (1e). Abbreviations: DC, dendritic cell; NK cell, natural killer cell.
effectively stimulate CD4+ T lymphocyte activation. Although this stimulation is advantageous in terms of generating IL-2 for effector lymphocyte, it could also promote an undesired regulatory T lymphocyte response. In addition, adenovirus cancer vaccines are generally suitable for co-administration with Toll-like receptor (TLR) agonists, whereas poxviruses tend to block TLR-activated dendritic cell maturation signals. 30, 53 Preclinical studies in a nonprostate cancer model have shown that combining Ad5-TAA vaccination with intratumoural administration of the TLR-9 agonist CpG (class B) results in a synergistic therapeutic benefit. 54 Furthermore, co-administration of Ad5-PSA or Ad5-OVA vaccines with a class B CpG has been shown to result in enhanced tumour destruction. 55, 56 Cell-based vaccines
The majority of cell-based cancer vaccines can be categori zed into two types. 57 The first type involves reinfusion of the patient's own antigen-presenting cells (APCs) treated with an appropriate TAA and is generally more labour-intensive. The second type involves transfection of irradiated allogeneic or autologous cancer cells with an immunostimulatory cytokine, and is less labour-intensive when allogeneic cancer cells are used.
Sipuleucel-T
The first FDA-approved prostate cancer vaccine, s ipuleucel-T, is available for the treatment of patients with metastatic CRPC. Sipuleucel-T consists of the patient's own peripheral blood mononuclear cells (PBMCs) that have undergone leukapheresis, been enriched for monocytic cells, and then treated with PA2024 (a recombi nant fusion protein of human PAP and GM-CSF). Patients receive three infusions of the prepared cells at biweekly intervals. The seminal integra ted phase III IMPACT trial has demonstrated a 4-month survival benefit with s ipuleucel-T compared with placebo (infusion with monocytic cells that have not been treated with PA2024). 5, 58 Interestingly, no change in time to disease progression was observed in men who received s ipuleucel-T compared with controls, despite the observed increases in survival. The absence of signs of measurable tumour regression or reduced tumour burden has puzzled clinicians, 59 particularly given that the mecha nism of action of sipuleucel-T is still unknown. It has been noted that patients who demonstrate increased survival benefit tend to express high titres of anti-PAP antibodies. However, an antibody-mediated form of tumour destruction is unlikely as PAP is not a cell surface protein. Although it seems logical to assume that PAP-specific CTLs are the primary mediators of immune-mediated tumour killing, there are no published clinical or preclinical data to support this theory. In fact, data show that sipuleucel-T is more efficient at genera ting antibody and T lymphocyte responses to the fusion product PA2024 than to PAP epitopes. 60 This is perhaps unsurprising, given that the fusion protein is non-self. Indirect evidence involving a rat model and a rat equivalent of sipuleucel-T suggests that this vaccine can d iminish immune tolerance to self-antigens. 61 It is worth noting that a controversial report has been published that contains previously unpublished data analyses from the IMPACT trial. 62 Posthoc subgroup analysis revealed a marked age-dependent difference in the median survival of patients receiving the placebo. Specifically, in the placebo group, patients aged <65 years survived, on average, 11 months longer than patients aged ≥65 years. In addition, it was found that sipuleucel-T had no significant effect on survival in patients aged <65 years. Thus, the observed overall survival benefit for the sipuleucel-T group seemed to be entirely reliant on the differential survival rates exhibited by older versus younger patients. Such a finding is at odds with findings that standard vaccinations and immunotherapies are less effective in the elderly. [63] [64] [65] [66] These investigators also highlighted substantial differences between the IMPACT placebo and treatment groups in terms of the number and status of the reinfused mononuclear cells. 62 Firstly, although all patients had 90% of their mononuclear cells removed, 35% of these cells were subsequently reinfused to patients in the sipuleucel-T-treated group, whereas only 12% were reinfused to patients in the placebo group. Secondly, for the sipuleucel-T arm, mononuclear cells were incubated with GM-CSF (in chimeric form) for 36-44 h at 37 °C, whereas, in the placebo group, mononuclear cells were not treated with GM-CSF and were incubated for 36-44 h at 2-8 °C-conditions that might result in substantial cell death. Repeated depletions of mononuclear cells could have had an adverse effect on the survival of older patients (age >65 years) as these men are less able to replenish circulating mononuclear cells. The fact that the placebo group were reinfused with significantly fewer mononuclear cells than the treatment group could explain the differences observed in survival between these two groups.
Here we describe a possible mechanism by which sipuleucel-T exerts its hypothesized antitumour effect in men with prostate cancer (Figure 3) . Vaccination involves an initial infusion with APCs (loaded in vitro with PAP-GM-CSF fusion protein), which are likely to travel to the spleen. 67 Clinical data suggest that these mature s ipuleucel-T APCs then activate CD4 + T lymphocytes. 60 IL-2 released by the activated CD4 + T lymphocytes could then promote proliferation of PAP-specific CD8 + T lympho cytes that have been stimulated directly by s ipuleucel-T APCs induced to cross-present PAP epitopes by the GM-CSF fusion protein. These activated CD8 + T lympho cytes would then be capable of tumour cell killing.
In the future, it might be possible to enhance the immuno potency of sipuleucel-T by increasing the total number or proportion (relative to total cell count) of dendritic cells that are transfused back into patients. Furthermore, a systematic review and meta-analysis of 17 clinical trials investigating dendritic-cell-based vaccine vectors for prostate cancer has suggested that the current route of sipuleucel-T delivery might not be optimal. 68 Thus, it might be worth investigating whether efficacy can be increased by targeting the lymph nodes (as opposed to the spleen). Finally, sipuleucel-T combination therapy that downregulates regulatory T lympho cyte numbers or function (for example, as has been achieved with PROSTVAC® VF combination therapy) or eliminates tumour-suppressive MDSCs might also be worth investigating. For example, in a murine tumour therapy model of both colon cancer and melanoma, it was shown that one administration of low-dose cyclophosphamide (50 mg/kg) given 4 days prior to vaccination with dendritic cells (pulsed with the appropriate tumour lysate) resulted in enhanced antitumour effects and significantly reduced levels of regulatory T lymphocytes in the spleen. 69 Sipuleucel-T could also benefit from being combined with low-dose cyclophosphamide, particularly given that the current delivery method for this vaccine results in the accumulation of the infused APCs within the spleen. In these studies, doxorubicin also enhanced antitumour activity, but only when given subsequent to vaccination. Furthermore, regulatory T lymphocyte levels were not reduced in the spleen.
GVAX-PCa GVAX (Biosante Inc., San Francisco, CA, USA) is the generic name for a range of cancer vaccines that contain whole tumour cells transfected with GM-CSF. 57 Although the patient's own tumour cells can be used, this is considered (as with sipuleucel-T) to be both labour intensive and limited by cell numbers. Alternatively, vaccines that utilize established allogeneic cell lines are under development for a range of cancers, including colorectal, breast, pancreatic, and prostate cancer. GVAX vaccines for prostate cancer (GVAX-PCa) comprise a mixture of two irradiated human prostate cancer cell lines, LNCaP and PC-3, which constitutively express GM-CSF. Phase I/II clinical trials of patients with metastatic CRPC have demon strated the safety, immuno genicity, and efficacy (in terms of increased survival) of GVAX-PCa administered intradermally as a prime plus multiple boosts in the presence and absence of radio therapy. 70 , 71 The presence of two common tumour cell lines in GVAX-PCa potentiates a range of tumour-targeting T lymphocytes and anti bodies with varying specificities, beyond just PAP and PSA. Specifically, a retrospective analysis of three phase I/II studies involving GVAX-PCa immuno therapy revealed the induction of autoantibodies to 33 antigens designated as potential targets for patients with CRPC. 72 Three of these proteins-galectin-8, TRAP-1, and TARP-are strongly linked to prostate cancer carcinogenesis and TARP antibody induction has been shown to have a significant association with clinical outcome (as d emonstrated by increased PSA doubling time [PSADT] ). The irradiated allogeneic LNCaP and PC-3 cells secrete recombinant GM-CSF, which chemotactically attracts immature host dendritic cells, induces dendritic cell maturation, and promotes cross-presentation of proteins derived from apoptotic GVAX-PCa cells (Figure 4) . Apoptotic bodies from irradiated tumour cells can be taken up by dendritic cells, as well as by B cells. Given that ionizing radiation can induce immunogenic cell death, it is possible that these apoptotic bodies promote their own dendritic-cell-mediated uptake and dendritic cell maturation via the expression of calreticulin and HMGB1, respectively. 73, 74 Mature dendritic cells expressing exo genously acquired tumour antigens could then activate both TAA-specific CD4 + T lymphocytes and CD8 + T lympho cytes. The activated CD4 + T lymphocytes might stimulate TAA-specific B lymphocytes and also provide IL-2 to TAA-specific CD8 + T lymphocytes. The TAA-specific antibodies to cell-surface proteins-which are produced by the activated B lymphocytes-could then induce tumour cell death via antibody-dependent cell-mediated cytotoxicity (ADCC) or a complementmediated pathway. In this model, activated CD8 + T lymphocytes would kill tumour cells by PCD upon recognition of MHC class I/TAA epitopes.
Combination therapy with GVAX-PCa
As for the PROSTVAC® VF cancer vaccine, the combination of GVAX-PCa with ipilimumab has been investigated in an open-label nonrandomized clinical trial. 75 This phase I study of GVAX-PCa and escalating doses of ipilimumab followed murine preclinical studies that suggested a synergy between ipilimumab and GM-CSFsecreting melanoma cells, 76 as well as two randomized phase III trials to show that ipilimumab improves survival in patients with metastatic melanoma. 77, 78 Initially, 12 patients were enrolled into a dose-escalation cohort and received doses of either 0.3 mg/kg (n = 3), 1.0 mg/kg (n = 3), 3.0 mg/kg (n = 3), or 5.0 mg/kg (n = 3) ipili mumab. The patients receiving the lowest two doses did not exhibit any severe immune-related adverse events; however, all three patients given the 3.0 mg/kg dose experi enced grade 2 or 3 hypophysitis (inflammation of the pituitary gland) and the patients receiving the 5.0 mg/kg dose exhibited either grade 3 hypo physitis (n = 2) or grade 4 sarcoid alveolitis (inflammation in the lungs; n = 1). Subsequently, 16 patients were enrolled into an expansion cohort to receive ipilimumab at 3 mg/kg in combination with GVAX-PCa. From this second (2), which then provide IL-2 (3b) to PAP-specific CD8 + T lymphocytes that interact with sipuleucel-T APCs (3a). These T lymphocytes then mediate programmed cell death of tumour cells (4) . Abbreviation: APC, antigen-presenting cell. study phase, it was concluded that, despite six patients experiencing grade 1-3 immune-related adverse effects (hypophysitis, colitis, or hepatitis), this combination was safe and well tolerated by patients. It is worth noting that co-administration of GVAX and the TLR-4 agonist LPS resulted in enhanced therapeutic outcomes for mice with melanoma, compared with GVAX alone. 79 Thus, future vaccinations with GVAX-PCa could benefit from the addition of danger signals capable of triggering TLRs.
Importantly, two phase III trials of GVAX-PCa (VITAL-1 and VITAL-2) were prematurely terminated, owing to lack of effect for VITAL-1 and increased mortality for VITAL-2. 80 In the VITAL-1 trial, GVAX-PCa was compared with docetaxel and prednisone chemo therapy, whereas the VITAL-2 trial compared the combination of GVAX-PCa and docetaxel with the standard treatment of docetaxel and prednisone. 81, 82 In a routine safety review of this trial, 67 deaths (33%) were reported in the GVAX-PCa plus docetaxel arm, compared with 47 deaths (23%) in the docetaxel plus prednisone arm. However, it has been suggested that these two trials were commenced prematurely and the FDA has recently relaxed its marketing restrictions on GVAX-PCa. 80 To elaborate, it has been argued that a phase II study should have been performed, prior to launching into the VITAL-2 trial, in order to evalu ate the optimal dose of docetaxel to be used in combi nation with GVAX-PCa. 80 In addition, the efficacy of GVAX-PCa in the VITAL-1 trial was compared with an established chemo therapeutic drug (docetaxel), but not a placebo control, in patients with advanced disease. Given these circumstances, it is unlikely that GVAX-PCa alone would yield impressive outcomes and some urologists have opined that this therapy should have been a dministered to patients with less advanced disease.
Aside from the recognized potential of combining docetaxel with GVAX-PCa, results from murine studies have suggested that other chemotherapeutic drugs are also potential candidates for combining with GM-CSFsecreting tumour cell vaccines. Specifically, in a prophylactic breast cancer model, it was shown that paclitaxel (20 mg/kg) and cyclophosphamide (100 mg/kg) could both independently enhance the antitumour activity of a GMCSF-expressing tumour cell vaccine, particularly when given 1 day prior to vaccination (as opposed to 7 days after vaccination). 83 These data suggest that increased antitumour responses are mediated by increased levels of tumour-specific T cells. By contrast, doxorubicin also enhances antitumour activity, but only when given subsequently to vaccination and without increasing levels of tumour-specific T cells. More recently, in a therapeutic study of a murine prostate tumour model, delivery of lowdose paclitaxel (4 mg/kg) 2 days prior to vaccination with a prostate tumour cell line (irradiated and surface-modified with GM-CSF) was significantly more effective at retarding tumour progression than paclitaxel, vaccine alone, or paclitaxel administered 4 days after vaccination. 84 Such a finding highlights the potential for combining low-dose chemotherapy with prostate cancer vaccines and emphasizes the importance of the sequence of a dministration of the vaccine and the chemotherapeutic agent.
DNA-based vaccines
DNA-based vaccination has been shown to be effective at promoting cellular immune responses in murine models, 85 supporting human clinical trials of prostate cancer vaccines that contain TAA-encoding plasmids. 86, 87 Two DNA vaccines that have reached clinical trials for use in men with prostate cancer are DNA-PAP and DNA-PSA.
DNA-PAP
In an open-label single-institution phase I/II clinical trial, 22 men with prostate cancer and signs of biochemical recurrence (but no evidence of metastatic disease) were vaccinated intradermally with a plasmid encoding human PAP (pTVG-HP) along with co-administration of GM-CSF (200 μg) over the course of 12 weeks (six times at fortnightly intervals). 86 No adverse effects were recorded for doses of DNA plasmid up to 1,500 μg. Of the 22 patients vaccinated, seven (32%) exhibited a twofold (or greater) increase in PSADT over a period of 12 months post-treatment. PAP-specific T-lymphocyte responses were detected in ten patients (45%) and a threefold (or greater) increase in PAP-specific CD8 + proliferative T lymphocytes was detected in three patients (14%). A follow-up review of this phase I trial was performed to garner additional immunological information that could be of use for optimizing vaccination protocols in future clinical trials. 87 It was determined that the more vaccinations given to patients, the greater the likelihood of generating PAP-specific T-lymphocyte responses. In T lymphocytes (1c'). Activated CD4 + T lymphocytes further stimulate B-lymphocyte activation (1d) and provide IL-2 for CD8 + T lymphocytes (1d'). B lymphocytes produce TAA-specific antibodies to cell-surface proteins that result in antibody-dependent cell-mediated cytotoxicity or complement-mediated tumour cell death (1e). Activated CD8 + T lymphocytes then kill tumour cells via recognition of MHC class I molecules in association with TAA epitopes (1e'). Abbreviation: DC, dendritic cell.
addition, six of the eight patients with long-term PAPspecific IFN-γ T lymphocyte responses exhibited >200% increases in PSADT, whereas only one of the 14 patients that demonstrated a <200% increase in PSADT developed a detectable response (P = 0.001).
DNA-PSA
In a phase I trial to evaluate the safety and feasibility of DNA-PSA, nine patients with advanced prostate cancer were given intradermal injections of a DNA plasmid encoding PSA (pVAX/PSA) over 20 weeks (five times at 4-weekly intervals). 88 In a preclinical study, subcutaneous injections of GM-CSF (40 μg/day over 3 days) and IL-2 (75 μg/day over 7 days) were co-administered to patients-commencing 2 days prior to vaccination for GM-CSF and 1 day subsequent to vaccination for IL-2-and the presence of these adjuvants was shown to be benefi cial. 89 Although various doses of pVax/PSA were tested (ranging from 100 to 900 μg), no dose-limiting toxici ties or grade 3/4 adverse effects were observed. Nor was there any evidence of autoimmune disease. All three patients receiving the highest dose of pVAX/PSA (900 μg; patients #7, #8, and #9) exhibited increased levels of PSA-specific IFN-γ-producing T lymphocytes, although, in one of these patients (#9), this increase was not statistically significant. Two of these three patients (#7 and #9) demonstrated increased PSADT, which c orrelated with immune response and disease stabilization.
The mechanism of action by which these TAAencoding plasmid DNA vaccines exert their effect might be similar to that of sipuleucel-T, with the major differences being the type of APC involved and the site of immune response induction (Figure 3) . We propose that intradermal administration of plasmid DNA encoding a prostate TAA (pDNA/TAA) is taken up and expressed primarily by specialized dermal dendritic cells, known as Langerhans cells. 90 GM-CSF, which is co-injected with pDNA/TAA, attracts immature Langerhans cells and induces their maturation. 91 Mature Langerhans cells then travel to draining lymph nodes, where upregulated levels of CD80 and CD86 (induced by GM-CSF) 92 and co-expressing MHC class I/TAA epitopes cause them to stimulate TAA-specific CD8 + T lymphocyte activation via interactions with CD28 and TCR, respectively. It is likely that some TAA epitopes are expressed in association with MHC class II molecules, resulting in the activation of CD4 + T lymphocytes. IL-2 released by these helper T cells could then activate TAA-specific CD8 + T lymphocytes, which are then capable of inducing PCD of tumour cells.
The main concern with using naked plasmid DNA in vaccines is the potential for inefficient transfection. Encouragingly, it has been shown that mice vaccinated with pVAX/PSA demonstrate significantly improved PSAspecific CD8 + T lymphocyte responses when vacci nation is combined with in vivo electroporation. 93 However, inexplicably, the magnitude of the transfection efficiency did not directly correlate with the magnitude of cellular immune responses when various electroporation conditions were tested, suggesting that electroporatio n p arameters must be carefully chosen.
Novel vaccine strategies
All of the prostate cancer vaccines discussed in this Review, with the exception of GVAX-PCa, involve the use of one specific TAA as an immunogen. One possible drawback of such an approach is that it might be too restrictive. For example, tumours could lose expression of a crucial epitope, rendering the TAA-specific CTL incapable of target recognition and, therefore, compromising effective antitumour activity. Attempts to address this issue have included the use of in situ tumour cells as the vaccine in order to generate a wide range of potential target TAAs, making it more difficult for the tumour to avoid immune eradication. To explain, in situ tumours can be induced via a variety of agents (such as ionizing radiation and anthracyclines) to undergo an immunogenic cell death, which can result in the generation of TAA-specific CTLs. [94] [95] [96] Dying cells that release purine nucleotides (such as ATP) and HMGB1 can chemotactically attract dendritic cells and promote their activation to favour the stimulation of antitumour CTL responses. 74, 97 Meanwhile, the induced expression of calreticulin on the surface of dying cells can promote their own uptake by these APCs. 17 Here we describe a novel method of inducing in situ immunogenic tumour cell death that has reached clinical trials for prostate cancer patients.
Gene-mediated cytotoxic immunotherapy
The mode of tumour cell death is important for alerting the host's immune system to endogenous TAAs expressed by the tumour cells. Chemotherapy generally triggers nonimmunogenic PCD. This pathway does not activate the innate immune system and, therefore, avoids the generation of a downstream TAA-specific CTL response. Evidence suggests that gene-mediated cytotoxic immunotherapy (GMCI)-mediated cell death is a strong inducer of innate immunity. 98 GMCI involves intra tumoural delivery of an adenovirus encoding the Herpes virus thymidine kinase (AdV-tk) gene. Transduced cells in the tumour microenvironment that express thymidine kinase then convert (by multiple phosphorylation events) a systemi cally administered prodrug-such as vala cyclovir (VCV) or ganciclovir (GCV)-from a low-affinity to a high-affinity nucleotide analogue that is toxic to dividing or DNA-repairing cells. 99, 100 The activated prodrug can then affect neighbouring cells via multiple processes, collectively known as the local bystander effect, which can include the spread of the active drug to neighbouring cells via GAP junctions or apoptotic vesicles. 101, 102 Importantly, GMCI also generates an immune-mediated systemic bystander effect that attacks metastases and p rotects against tumour rechallenge.
103-105
The mechanism by which GMCI stimulates antitumour immunity is likely to be similar to that described for GVAX-PCa (Figure 4) . Apoptotic tumour cells are likely to be taken up by immature dendritic cells and B lympho cytes (possibly as a result of cell-surface expression of calreticulin) and certain tumour components (such as HMGB1 or other viral components) contribute to dendritic cell maturation. Mature dendritic cells would then directly activate tumour-antigen-specific CD4 + and CD8 + T lymphocytes. The activated CD4 + T lymphocytes further stimulate B lymphocyte activation and release IL-2, which activates CD8 + T lymphocytes. B lymphocytes produce TAA-specific antibodies to cell surface proteins that mediate ADCC or complement-mediated tumour cell death, and activated CD8 + T lymphocytes kill tumour cells upon recognition of TAA/MHC class I epitopes.
In a phase I/II clinical trial, GMCI (AdV-tk plus prodrug) was administered to 23 men with locally advanced prostate cancer prior to prostatectomy. 106 Analysis of the resected prostates revealed a substantial influx of CD8 + T lymphocytes into the tumours of treated patients that was significantly higher than that observed in tumours from control patients. 2 weeks after treatment, circulating blood levels of activated CD8 + T lymphocytes were significantly elevated compared with pretreatment levels. This effect was in contrast to the changes observed in levels of activated CD4 + T lymphocytes (remained the same), natural killer cells (decreased), and B lymphocytes (remained the same). Although treatment did not result in improved prognosis (in terms of biochemical recurrence rates), valuable information was obtained from this study. For example, GMCI demonstrated c ytopathological effects in cancerous, but not benign, tissue.
However, the lack of improved prognosis prompted investigators to combine standard therapies (such as radiotherapy) with GMCI. Radiation causes DNA damage, which increases DNA repair activity and, therefore, renders cancer cells more sensitive to GMCI. A phase I/II clinical trial of GMCI plus radiotherapy has been performed, involving 59 patients with varying stages of prostate cancer. 107 This cohort included 29 patients at low risk (stage T1-T2a, Gleason score <7), 26 patients at high risk (stage T2b-T3, Gleason score >6), and four patients with stage D1 prostate cancer. Encouragingly, biopsy data have revealed good loco regional control in both low-risk and high-risk patients. At median f ollowup intervals of >13 months, biochemical control of PSA levels was also noted for all low-risk and high-risk patients. However, two out of four patients with stage D1 disease experienced biochemical failure at 3 months (one other patient experienced biochemical failure at 7 months and the remaining patient still had biochemical control at last follow-up visit).
Future of prostate cancer vaccines
It is becoming increasingly clear that men with less advanced disease are more likely to benefit from prostate cancer vaccines. 21 At some stage, it makes sense for these vaccines to be tested under conditions that maximize their potential. However, concerns regarding patient safety mean that this is not yet feasible. Following the widespread introduction of sensitive screening methods, the majority (>90%) of men with prostate cancer are now diagnosed without detectable metastatic disease. Given that a substantial percentage (>30%) of these patients will eventually develop metastatic disease, a strong argument can be made for early vaccination. Further encouragement can be derived from the fact that these vaccines have proven to be safe and well tolerated in virtually all prostate cancer vaccine trials. Additionally, these treatments seem to slow disease progression or, at the very least, do not accelerate it.
It seems likely that administering cancer vaccines at an early stage of disease management would result in only a minimal risk of serious adverse effects and could potentially offer substantial life-extending benefits. Skepticism as to whether prostate cancer TAAs, such as PSA and PAP, are viable targets for CTLs has been largely quashed by the finding that vaccines induce prostate cancer TAAspecific CD8 + T lymphocyte responses in many men with prostate cancer. 50, 86 Such findings discount the possibility that prostate-specific T lymphocytes are deleted via central tolerance mechanisms. Ideally, prostate cancer vaccines would be administered prior to surgical resection, particularly during the initial assessment of a new vaccine, so that the postvaccination tumour milieu can be ascertained. The ratio of tumour-specific lymphocytes (or CD8 + T lymphocytes, at least) to suppressor cells, such as regulatory T lymphocytes and MDSCs, could be determined as an indication of the efficacy of the vaccine and could subsequently be correlated with other clinical parameters such as changes in PSADT or time to disease progression. Such an approach could provide valuable information for modifying vaccine protocols.
It is likely that prostate cancer vaccination in patients with more advanced disease is less effective, owing to a combination of factors, including excessive tumour burden, the accumulation of tumour-suppressive elements (such as regulatory T lymphocytes and MDSCs), and the intrinsic suppressive nature of the tumour itself. It is imperative that future therapies involve combinations of an effective cancer vaccine with a safe, but potent, dampening (or elimination) of suppressive populations. Clinical trials of PROSTVAC® VF in combination with agents that reduce regulatory T lymphocyte involvement (including antibodies, ipilimumab, and MDX-1106) have shown potential. 36, 108 Although it is too early to assess the efficacy of these combinations, these therapies represent a 'step in the right direction' for prostate cancer care. However, if all immuno suppressive elements, including metastatic tumour burden, are to be effectively dampened (with regulatory T lymphocytes) or eliminated (with MDSCs and tumour cells), a multipronged treatment approach might be necessary and validation of such an approach could involve many years of clinical trials. A potential 'shortcut' or 'stop-gap approach' could involve strategic low-dose c hemotherapy as an adjunct to prostate cancer vaccination.
Trials of docetaxel and either PROSTVAC® VF or GVAX-PCa occurred more by happenstance than through any strategy designed to fully exploit the vaccines' antitumour potential. To explain, combining prostate cancer vaccines with docetaxel has stemmed from the fact that docetaxel (plus prednisone) has been the gold standard for treatment of patients with CRPC, not from any findings to suggest that docetaxel would enhance the efficacy of cancer vaccines more than other chemotherapeutic drugs. Although docetaxel reduces tumour burden and is thought to enhance T-cell effector function, it has no preferential toxicity for immunosuppressive cell populations and, therefore, is unlikely to significantly enhance the efficacy of cancer vaccines. At low doses, the chemothera peutic drugs cyclophosphamide and 5-fluorouracil are independently capable of dampening regulatory T lympho cyte function and eliminating MDSCs, respectively. 43, 44 Thus, combining prostate cancer vaccination with low-dose cyclophosphamide and 5-fluorouracil regimens could have a synergistic effect on immune and therapeutic outcomes for men with prostate cancer. More recently, it has been shown in phase III clinical trials involving patients with metastatic CRPC that anti androgens such as abiraterone and enzalutamide can significantly extend overall survival compared with placebo. 109, 110 Both drugs have received FDA approval and could be of benefit when combined with prostate cancer vaccines.
Conclusions
Over the past decade, results from clinical trials of men with prostate cancer at varying stages of disease treated with various vaccination strategies have highlighted some important factors. Firstly, the parameters required for measuring clinical end points for therapeutic cancer vaccines are likely to be different to those used for chemotherapy. Overall survival is, ultimately, the best parameter for monitoring treatment success; however, extensive time lags between treatment initiation and death mean that data collection is time consuming. PSADT is considered to be a more reliable parameter for assessing cancer vaccine efficacy than serum PSA levels. However, although PSADT has been shown to correlate well with overall survival in patients with biochemical recurrence after radical prostatectomy, there is concern as to the restrictions such measurements place on the timing and nature of subsequent therapies for these patients. 111, 112 Thus, in situations when PSADT monitoring is inappropriate or impractical, a more appropriate end point might be time to disease progression. Another parameter that is gaining attention is the T lymphocyte stimulation index, which has been shown to correlate with cancer vaccine efficacy. 113 Finally, in terms of treatment protocol, it is important to consider the timing of vaccination with respect to disease status and whether the vaccine should be delivered preoperatively or postoperatively.
Overall, clinical trials have shown that prostate cancer vaccines are safe and effective. Conclusions regarding the efficacy of individual vaccines are premature at present. Nevertheless, some tentative predictions can be made. Of the vaccines tested in clinical trials, the most advanced is sipuleucel-T. However, the labour and costs involved in generating this individualized vaccine represent an important drawback, particularly in light of the recent reanalysis of IMPACT trial data, which questions the therapeutic benefit of sipuleucel-T. 62 Changing the administration route of sipuleucel-T such that it targets lymph nodes instead of, or in addition to, the spleen could provide therapeutic benefit. 68 Data regarding plasmid DNA/TAA vaccinations are promising but the limited efficiency of transfection and subsequent strength of T-lymphocyte responses remain potential drawbacks. In addition, virusbased cancer vaccines seem to perform the same function as DNA-based vaccines, only much more efficiently.
Although there have been fewer clinical studies of Ad5-based vaccines compared with poxvirus-based vaccines (such as PROSTVAC® VF), the results obtained for the Ad5-PSA vaccines are promising and warrant further clinical evaluation. As none of the prostate cancer vaccines discussed here are likely to be used as stand-alone therapies, it is important that they can be combined with other therapeutic agents, such as TLR agonists, chemotherapeutic drugs, and agents that dampen regulatory T lymphocyte function (such as anti-CTLA-4 and anti-PD-1 anti bodies). In summary, the clinical trials performed thus far could pave the way for great advances in prostate cancer therapy, involving strategically designed combinatorial therapies that synergistically promote vaccine-induced antitumour immunity.
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